Safety Study of AMG 228 to Treat Solid Tumors

Study summary

The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedAMG 228

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 8, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?Amgen

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Amgen
Interventions being studied: Drug: AMG 228

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Subject must have a pathologically documented, definitively diagnosed, advanced solid tumor
Adequate hematological, renal, hepatic, and coagulation laboratory assessments

Reasons someone may not be able to joinExclusion criteria

Active autoimmune disease, history of autoimmune disease
Treatment with immune modulators including
Use of warfarin, factor Xa inhibitors, or direct thrombin inhibitors
Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 days
Major surgery within 28 days of study day 1

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Research SiteLa Jolla, California
Research SiteNew Haven, Connecticut
Research SiteNew York, New York
Research SiteParkville, Victoria
Research SiteLeuven
Research SiteVillejuif
Research SiteHeidelberg

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 8, 2022. Always confirm current availability with the study team.

View original record ↗